...
首页> 外文期刊>Brain research >Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson's disease.
【24h】

Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson's disease.

机译:阿扑吗啡在帕金森氏病的6-OHDA纹状体大鼠模型中的神经保护作用和神经营养作用。

获取原文
获取原文并翻译 | 示例

摘要

We investigated the possible neuroprotective effect of the dopamine (DA) receptor agonist R-apomorphine (R-APO) within the striatal 6-hydroxydopamine (6-OHDA) rat model of Parkinson's disease. In one group of rats, R-APO administration (10 mg/kg/day, s.c.) started 15 min before 6-OHDA-injection. In a second group, R-APO administration started 24 h after lesion induction. Both groups received R-APO chronically for 11 days. Testing was carried out 2 weeks post-lesioning. R-APO treatment, whether started before or after the lesion induction, significantly reduced both the amphetamine-induced ipsiversive rotation and the size of the lesion at the level of the substantia nigra. Moreover, the dopamine cell shape and size resembled that observed in intact animals. R-APO treatment had no effect on the number of cells in the substantia nigra of intact rats, but significantly increased the number of cells in the ventral tegmental area (VTA), suggesting selective neurotrophic properties of R-APO in this region. R-APO treatment significantly attenuated the 6-OHDA-induced striatal DA depletion and DOPAC/DA ratios were normalized. Finally, an acute injection of 10 mg/kg R-APO was unable to scavenge 6-OHDA or MPP(+)-induced hydroxyl radicals as determined with the in vivo salicylate trapping technique. These data provide further evidence of the neurorescuing properties of R-APO. At least at the dose used in this study, this effect possibly occurs via mechanisms other than scavenging of hydroxyl radicals. In intact rats, we also show neurotrophic effects of the R-APO treatment. These seem to be limited to the VTA.
机译:我们研究了帕金森氏病的纹状体6-羟基多巴胺(6-OHDA)大鼠模型中多巴胺(DA)受体激动剂R-阿扑吗啡(R-APO)的可能的神经保护作用。在一组大鼠中,在注射6-OHDA之前15分钟开始R-APO给药(10 mg / kg /天,皮下注射)。在第二组中,在病变诱导后24小时开始R-APO给药。两组均长期接受R-APO治疗11天。损伤后2周进行测试。 R-APO治疗,无论是在病变诱发之前还是之后开始,都可以显着减少苯丙胺诱发的旋转性转动和在黑质水平上的病变大小。此外,多巴胺细胞的形状和大小类似于在完整动物中观察到的形状和大小。 R-APO处理对完整大鼠黑质中的细胞数量没有影响,但显着增加了腹侧被盖区(VTA)中的细胞数量,表明R-APO在该区域具有选择性的神经营养特性。 R-APO处理显着减轻了6-OHDA引起的纹状体DA消耗,并且DOPAC / DA比率正常化。最后,如体内水杨酸酯捕获技术所确定的那样,急性注射10 mg / kg R-APO无法清除6-OHDA或MPP(+)诱导的羟基自由基。这些数据提供了R-APO的神经拯救特性的进一步证据。至少在本研究中使用的剂量下,这种作用可能是通过清除羟基自由基以外的其他机制发生的。在完整的大鼠中,我们还显示了R-APO治疗的神经营养作用。这些似乎仅限于VTA。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号